GT Biopharma (GTBP) to Release Earnings on Thursday

GT Biopharma (NASDAQ:GTBP) is projected to post its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect GT Biopharma to post earnings of ($0.38) per share for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 7:00 AM ET.

GT Biopharma (NASDAQ:GTBP) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.13. On average, analysts expect GT Biopharma to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GT Biopharma Stock Performance

Shares of GTBP stock opened at $0.61 on Thursday. GT Biopharma has a fifty-two week low of $0.55 and a fifty-two week high of $4.10. The firm has a market capitalization of $2.17 million, a price-to-earnings ratio of -0.15 and a beta of 1.38. The stock’s 50-day simple moving average is $0.75 and its 200-day simple moving average is $1.77.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, October 8th. Wall Street Zen lowered GT Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.